Tenet generates $164M in Q2 ambulatory care adjusted EBITDA: 12 takeaways

Tenet Healthcare accrued substantial net losses from continuing operations in the second quarter this year.

Advertisement

Here are 12 takeaways:

Full company
1. Net losses from continuing operations attributed to Tenet shareholders were $56 million, up from $44 million net losses in the second quarter last year.

2. Adjusted EBITDA totaled $570 million, less than $629 million in the same quarter of 2016.

3. Cash and cash equivalents totaled $475 million as of June 30.

4. Tenet had $1.375 billion in uncompensated care costs.

Ambulatory care segment
5. Tenet generated net operating revenues of $472 million, up 6.8 percent compared to the same quarter last year.

6. Tenet’s ambulatory segment had adjusted EBITDA of $164 million, an 18 percent increase from the same quarter of 2016.

Hospital operations and other segment
7. Patient revenue was nearly $4.04 billion on a same-hospital basis.

8. Net operating revenues were $4.06 billion, a 0.1 percent drop from the second quarter of 2016.

9. Adjusted EBITDA was $346 million.

10. The company’s health plan businesses accrued losses of $19 million.

2017 outlook
11. Tenet expects revenue between $19.1 billion and $19.4 billion.

12. The company anticipates adjusted EBITDA between $2.45 billion and $2.55 billion.

More articles on surgery centers:
7 things for ASC leaders to know for Thursday — Aug. 10, 2017
Buena Vista Surgery increases case volume by 10% by making it easier for physician offices to coordinate cases: 4 key takeaways
9 hospitals, health systems opening or planning ASCs — July 2017

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in ASC Transactions & Valuation Issues

Advertisement

Comments are closed.